Clinical trials: Depression NOS
Major Depressive Disorder
Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine
This study was a pharmacokinetic and safety evaluation of the S-adenosylmethionine formulation MSI-195, and a commercial comparator. The study was broken into two stages.
- Trial name
- NCT04623034
- Testing
- Ademetionine
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- MSI Methylation Sciences, Inc.
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Depression Study In Elderly Patients
Major Depressive Disorder (MDD) Study in Elderly Outpatients
- Trial name
- NCT00067444
- Testing
- Paroxetine CR
- Where
- 46 sites in United States
- Volunteers
- 560 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depressive Disorder, Major
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.
- Trial name
- NCT01870843
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 261 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Depression
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
- Trial name
- NCT00624858
- Testing
- naltrexone SR 32 mg/ bupropion SR 360 mg daily
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Orexigen Therapeutics, Inc
Depressive Disorder, Major
Duloxetine in the Treatment of Melancholic Depression
The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose.
- Trial name
- NCT00191685
- Testing
- duloxetine
- Where
- 23 sites in Australia, Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Treatment-resistant Depression
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-2 (NCT02497287)
- Testing
- Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 109 sites in United States, Argentina and 19 more
- Volunteers
- 802 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01153009
- Testing
- Vortioxetine, Duloxetine
- Where
- 56 sites in United States
- Volunteers
- 614 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Bipolar Depression
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
The purpose of this study is to evaluate the efficacy, safety, and tolerability of cariprazine in the treatment of outpatients with bipolar depression.
- Trial name
- NCT00852202
- Testing
- cariprazine
- Where
- 26 sites in United States
- Volunteers
- 234 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
- Trial name
- NCT00242229
- Testing
- DVS-233 SR
- Volunteers
- 52 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Bipolar Depression, Bipolar Disorder
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models. This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses…
- Trial name
- NCT00908154
- Testing
- GSK1014802
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Biogen
Depressive Disorder, Major
Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)
Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.
- Trial name
- NCT03668600
- Testing
- Rapastinel
- Where
- 74 sites in United States
- Volunteers
- 230 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Parkinson Disease
Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's Disease
To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by determination of the prevalence of depression in PD…
- Trial name
- NCT00752388
- Where
- 278 sites in Germany
- Volunteers
- 1,588 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder (MDD)
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50 mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week double-blind phase and a 52-week open-label phase.
- Trial name
- NCT00411242
- Testing
- agomelatine
- Where
- 51 sites in United States
- Volunteers
- 503 people
- Sponsor
- Novartis
Anxiety, Depression, Anxiety
Study to Identify if OVR Health's VR-Kit is Safe to Use and Helps to Improve Focus, Attention and Reduce Worry & Rumination.
This is a randomized-controlled interventional treatment study with three arms of comparable demographics to evaluate the safety and efficacy of OVR Health's VR experience to improve control over the focus of attention and reduce…
- Trial name
- NCT05291429
- Testing
- OVR Health's VR experience
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Oxford VR
Major Depressive Disorder
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects.
- Trial name
- NCT00952653
- Testing
- Desvenlafaxine Succinate Sustained Release, Midazolam
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Major Depressive Disorder
Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration
This is a study to assess the distribution, metabolism and excretion of [14C]AZD6765 after a single-dose intravenous administration.
- Trial name
- AZD6765 (NCT01217645)
- Testing
- 150 mg [14C] AZD6765
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca